

## Freedom of Information request 641-22

---

### Request

Please may you tell me how many patient initiations were recorded from January 2019 to October 2022, monthly and moving annual total (i.e. Nov-21 to Oct-22) for:

1. Olaparib (Lynparza®) capsules as monotherapy (SMC No. 1047/15) for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy (November 2016)
2. Olaparib (Lynparza®) tablets as monotherapy (SMC2209) for the maintenance treatment of adult patients with newly diagnosed advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first line platinum-based chemotherapy (December 2019)
3. Olaparib (Lynparza®) tablets as monotherapy (SMC2367) for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (August 2021)
4. Olaparib (Lynparza®) tablets in combination with bevacizumab (SMC2368) for the maintenance treatment of adults with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (December 2021)
5. Olaparib (Lynparza®) as monotherapy (SMC2366) for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent (October 2021)

### Response

1. NHS Borders had no patient initiations in this category from January 2019 to October 2022.
2. NHS Borders had <5 patients initiated in this category from January 2019 to October 2022. The moving annual total for the period November 2021 to October 2022 was <5 patients.
3. NHS Borders had <5 patients initiated in this category from January 2019 to October 2022. The moving annual total for the period November 2021 to October 2022 was <5 patients.
4. NHS Borders had <5 patients initiated in this category from January 2019 to October 2022. The moving annual total for the period November 2021 to October 2022 was 0 patients.
5. NHS Borders had no patient initiations in this category from January 2019 to October 2022.

Please note that as NHS Borders is such a small Board the number of patient initiations is very small, and to provide further details (e.g., monthly figures) could allow individuals to be identified and we would be in breach of the Data Protection Act 2018. We are therefore withholding all other data under Section 38(2)(ii) of the Freedom of Information (Scotland) Act 2002. This is also in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld

to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [foi.enquiries@borders.scot.nhs.uk](mailto:foi.enquiries@borders.scot.nhs.uk).

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **641-22** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.